PDGFR alpha/KIT Mutant-specific Inhibitor BLU-285

Known as: BLU-285 
An orally bioavailable inhibitor of specific mutated forms of platelet-derived growth factor receptor alpha (PDGFR alpha; PDGFRa) and mast/stem cell… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2017-2017
012320172017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
  • Cancer discovery
  • 2018
The small-molecule inhibitor BLU-285 inhibits clinically relevant KIT and PDGFRA mutations. 
Is this relevant?
2018
2018
  • Cancer discovery
  • 2018
In a phase I trial of avapritinib (formerly BLU-285), which targets D816V mutant KIT, for the treatment of advanced systemic… (More)
Is this relevant?
2017
2017
  • Cancer discovery
  • 2017
Tyrosine kinase inhibitors may initially control gastrointestinal stromal tumors, but most patients eventually experience disease… (More)
Is this relevant?
2017
2017
for optimism: the findings of Jawhar and colleagues provide a molecular footing to help navigate the steep mountain toward cure… (More)
Is this relevant?
2017
2017
Targeting oncogenic kinase drivers with small-molecule inhibitors can have marked therapeutic benefit, especially when… (More)
Is this relevant?